Date: 2013-12-05
Type of
information: Recruitment of the first patient
phase: 1
Announcement: recruitment of the first patient
Company: Bayer (Germany)
Product: kinase inhibitor program
Action
mechanism:
Disease: advanced cancer
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news: * On
December 5, 2013, the Lead Discovery Center GmbH (LDC) has announced that an innovative kinase inhibitor program
licensed to Bayer Pharma in 2011, has been progressed to clinical trials. By 2012, Bayer had successfully advanced a lead compound from the program to the preclinical development stage. This fall, Bayer enrolled the first participant into a Phase I study to determine the safety, tolerability and pharmacokinetic profile in patients with advanced cancer. The licensed program included a lead structure from a chemical series of selective kinase inhibitors with potential for improving cancer treatment originally discovered by LDC. This lead structure was further optimized by Bayer scientists to provide a candidate suitable for clinical development.
Is
general: Yes